Bright Minds Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Bright Minds Biosciences has a total shareholder equity of CA$6.1M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$6.3M and CA$178.6K respectively.
Key information
0%
Debt to equity ratio
CA$0
Debt
| Interest coverage ratio | n/a |
| Cash | CA$6.19m |
| Equity | CA$6.10m |
| Total liabilities | CA$178.63k |
| Total assets | CA$6.28m |
Recent financial health updates
Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth
Oct 16
Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely
Aug 19We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully
Mar 07We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely
Nov 04Recent updates
Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth
Oct 16Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely
Aug 19We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully
Mar 07We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely
Nov 04Financial Position Analysis
Short Term Liabilities: DRUG's short term assets (CA$6.3M) exceed its short term liabilities (CA$178.6K).
Long Term Liabilities: DRUG has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: DRUG is debt free.
Reducing Debt: DRUG has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DRUG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: DRUG has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 17% each year.